|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
5. Traitements
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
Gilead Overspends to Quiet Deal Clamor [Bloomberg]
|
|
|
|
|
|
There's
a price tag on everything, possibly even happiness. For Gilead Sciences
Inc. shareholders irate over the company's multi-year case of the deal
yips as its growth stagnates, happiness apparently costs about $12
billion.
|
|
|
|
|
|
|
Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug [Forbes]
|
|
|
|
|
|
But
will that mean more controversy, too, as happened with Sovaldi, where
Gilead cured a disease but was vilified for the price it charged?
Milligan hopes not, pointing to the high price of cancer drugs in
general. In fact, he says, the one-time cost of Axi-Cel could wind up
being cheaper than long-term treatment with combinations of expensive
drugs, like Merck’s Keytruda or Bristol-Myers Squibb’s Opdivo.
|
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
Two New Therapies Approved for Acute Myeloid Leukemia [NCI]
|
|
|
|
|
|
The
Food and Drug Administration (FDA) recently approved two new treatments
for some adult patients with acute myeloid leukemia (AML): enasidenib
(Idhifa®), a drug that targets aberrant forms of the IDH2 protein; and
liposomal cytarabine-daunorubicin CPX-351 (Vyxeos™), a two-drug
chemotherapy combination encapsulated in tiny fatlike particles called
liposomes.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
A New Way for Doctors to Share Their Medical Mysteries [Wired]
|
|
|
|
|
|
Cureus
is the first and only peer-reviewed publication with step-by-step
article templates for authors—which dramatically speeds up publication
times. (Just like your tax software!) If case studies are published in
weeks instead of months, that means millions more medical lessons to
learn from.
|
|
|
|
|
|
|
6.7.1 Bioinformatique
|
|
|